Our Science
With about 575 scientists, Aurigene has developed
deep expertise in various target classes >>More
Trackrecord
Track-record of over 35 programs in collaboration with some of the leading global Pharma partners >>More
Our Focus
A specialized, discovery stage biotech, developing novel and best-in-class therapies to treat Oncology & Inflammation >>More
News
- 14th Apr 2011: Debiopharm and Aurigene sign a...
- 13th Sep 2010: Debiopharm Group™ and Aurige...
- 9th Sep 2010: Aurigene and Pcovery in pact t...
- 1st Sep 2009: Aurigene Announces Completion ...
- 3rd Feb 2009: Aurigene Announced Significant...
- 24th Nov 2008: Aurigene in licensing agreemen...
- 25th Jun 2008: Aurigene Achieves 2nd Mileston...
- 25th Apr 2007: Orion and Aurigene to Collabor...
- 2nd Feb 2007: Discovery Collaborations with ...
- 28th Jun 2006: Agreement with Debiopharm on I...
Events
- 18th Jun 2012: 2012 Bio International Convent...
- 31st Mar 2012: AACR Annual Meeting 2012
- 25th Mar 2012: 243rd ACS National Meeting �...
- 19th Feb 2012: Tri-Con 2012
- 5th Feb 2012: Keystone Symposia : Th17 Cells...
- 30th Jan 2012: 4th Immunotherapeutics and Imm...
- 9th Jan 2012: J.P. Morgan 2012 Healthcare Co...
- 13th Dec 2011: AACR: New Horizons in Cancer R...
- 4th Dec 2011: Natural Peptides to Drugs
- 30th Nov 2011: CPhI India Conference 2011